These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24033149)

  • 1. Mutations of the GATA2 and CEBPA genes in paediatric acute myeloid leukaemia.
    Shiba N; Funato M; Ohki K; Park MJ; Mizushima Y; Adachi S; Kobayashi M; Kinoshita A; Sotomatsu M; Arakawa H; Tawa A; Horibe K; Tsukimoto I; Hayashi Y
    Br J Haematol; 2014 Jan; 164(1):142-5. PubMed ID: 24033149
    [No Abstract]   [Full Text] [Related]  

  • 2. GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations.
    Green CL; Tawana K; Hills RK; Bödör C; Fitzgibbon J; Inglott S; Ancliff P; Burnett AK; Linch DC; Gale RE
    Br J Haematol; 2013 Jun; 161(5):701-705. PubMed ID: 23560626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.
    Hou HA; Lin YC; Kuo YY; Chou WC; Lin CC; Liu CY; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
    Ann Hematol; 2015 Feb; 94(2):211-21. PubMed ID: 25241285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations.
    Marceau-Renaut A; Guihard S; Castaigne S; Dombret H; Preudhomme C; Cheok M
    Am J Hematol; 2015 May; 90(5):E93-4. PubMed ID: 25611491
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical and genetic background of familial myelodysplasia and acute myeloid leukemia].
    Király PA; Kállay K; Marosvári D; Benyó G; Szőke A; Csomor J; Bödör C
    Orv Hetil; 2016 Feb; 157(8):283-9. PubMed ID: 26876264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.
    Pabst T; Eyholzer M; Haefliger S; Schardt J; Mueller BU
    J Clin Oncol; 2008 Nov; 26(31):5088-93. PubMed ID: 18768433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis.
    Fasan A; Eder C; Haferlach C; Grossmann V; Kohlmann A; Dicker F; Kern W; Haferlach T; Schnittger S
    Leukemia; 2013 Feb; 27(2):482-5. PubMed ID: 22814295
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.
    Theis F; Corbacioglu A; Gaidzik VI; Paschka P; Weber D; Bullinger L; Heuser M; Ganser A; Thol F; Schlegelberger B; Göhring G; Köhne CH; Germing U; Brossart P; Horst HA; Haase D; Götze K; Ringhoffer M; Fiedler W; Nachbaur D; Kindler T; Held G; Lübbert M; Wattad M; Salih HR; Krauter J; Döhner H; Schlenk RF; Döhner K
    Leukemia; 2016 Nov; 30(11):2248-2250. PubMed ID: 27375010
    [No Abstract]   [Full Text] [Related]  

  • 9. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.
    Greif PA; Dufour A; Konstandin NP; Ksienzyk B; Zellmeier E; Tizazu B; Sturm J; Benthaus T; Herold T; Yaghmaie M; Dörge P; Hopfner KP; Hauser A; Graf A; Krebs S; Blum H; Kakadia PM; Schneider S; Hoster E; Schneider F; Stanulla M; Braess J; Sauerland MC; Berdel WE; Büchner T; Woermann BJ; Hiddemann W; Spiekermann K; Bohlander SK
    Blood; 2012 Jul; 120(2):395-403. PubMed ID: 22649106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation.
    Renneville A; Mialou V; Philippe N; Kagialis-Girard S; Biggio V; Zabot MT; Thomas X; Bertrand Y; Preudhomme C
    Leukemia; 2009 Apr; 23(4):804-6. PubMed ID: 18946494
    [No Abstract]   [Full Text] [Related]  

  • 11. CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.
    Grossmann V; Haferlach C; Nadarajah N; Fasan A; Weissmann S; Roller A; Eder C; Stopp E; Kern W; Haferlach T; Kohlmann A; Schnittger S
    Br J Haematol; 2013 Jun; 161(5):649-658. PubMed ID: 23521373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline Predisposition to Hematolymphoid Neoplasia.
    Weinberg OK; Kuo F; Calvo KR
    Am J Clin Pathol; 2019 Aug; 152(3):258-276. PubMed ID: 31309983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CEBPA and GATA2 mutation and a transient blood group discrepancy in a patient with acute myeloid leukaemia.
    Flores-Morán MS; Fuste E
    Transfus Med; 2024 Oct; 34(5):457-458. PubMed ID: 39183374
    [No Abstract]   [Full Text] [Related]  

  • 14. Inherited predisposition to acute myeloid leukemia.
    Godley LA
    Semin Hematol; 2014 Oct; 51(4):306-21. PubMed ID: 25311743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).
    Brown AL; Hahn CN; Scott HS
    Blood; 2020 Jul; 136(1):24-35. PubMed ID: 32430494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial myelodysplasia and acute myeloid leukaemia--a review.
    Owen C; Barnett M; Fitzgibbon J
    Br J Haematol; 2008 Jan; 140(2):123-32. PubMed ID: 18173751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor prognosis in familial acute myeloid leukaemia with combined biallelic CEBPA mutations and downstream events affecting the ATM, FLT3 and CDX2 genes.
    Carmichael CL; Wilkins EJ; Bengtsson H; Horwitz MS; Speed TP; Vincent PC; Young G; Hahn CN; Escher R; Scott HS
    Br J Haematol; 2010 Aug; 150(3):382-5. PubMed ID: 20456351
    [No Abstract]   [Full Text] [Related]  

  • 18. Myelodysplastic features in a patient with germline CEBPA-mutant acute myeloid leukaemia.
    Yan B; Ng C; Moshi G; Ban K; Lee PL; Seah E; Chiu L; Koay ES; Liu TC; Ng CH; Chng WJ; Koh LP
    J Clin Pathol; 2016 Jul; 69(7):652-4. PubMed ID: 27010436
    [No Abstract]   [Full Text] [Related]  

  • 19. Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML.
    Mulet-Lazaro R; van Herk S; Erpelinck C; Bindels E; Sanders MA; Vermeulen C; Renkens I; Valk P; Melnick AM; de Ridder J; Rehli M; Gebhard C; Delwel R; Wouters BJ
    Blood; 2021 Jul; 138(2):160-177. PubMed ID: 33831168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression.
    Heyes E; Wilhelmson AS; Wenzel A; Manhart G; Eder T; Schuster MB; Rzepa E; Pundhir S; D'Altri T; Frank AK; Gentil C; Woessmann J; Schoof EM; Meggendorfer M; Schwaller J; Haferlach T; Grebien F; Porse BT
    Nat Commun; 2023 Oct; 14(1):6185. PubMed ID: 37794021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.